BioSpace News Archive

Inventiva (Euronext Paris and Nasdaq: IVA), a clinical-stage biopharmaceutical company focused on the development of oral small molecule therapies for the treatment of non-alcoholic steatohepatitis (NASH), mucopolysaccharidoses (MPS) and other diseases with significant unmet medical needs, today announced that five scientific abstracts have been selected for poster presentations during the upcoming The Liver Meeting™.

Terns Pharmaceuticals, Inc. today announced that three abstracts detailing clinical data for multiple non-alcoholic steatohepatitis (NASH)

Paratek Pharmaceuticals, Inc. (Nasdaq: PRTK) today announced that the first patient has been enrolled in the company’s Phase 2b study evaluating the safety and efficacy of NUZYRA ® (omadacycline) for the treatment for nontuberculous mycobacterial (NTM) pulmonary disease

Calithera Biosciences, Inc. (Nasdaq: CALA), a clinical-stage, precision oncology biopharmaceutical company, today announced an agreement with Takeda Pharmaceutical Company Limited (“Takeda”) to acquire two clinical-stage compounds, both of which have demonstrated single-agent clinical activity with the greatest potential in biomarker-defined cancer-patient populations.

Profound Medical Corp. will announce its third quarter 2021 financial results after market close on Thursday, November 4, 2021.

Yuman Fong, M.D., the Sangiacomo Family Chair in Surgical Oncology at City of Hope, a world-renowned cancer research and treatment organization, was presented with one of the highest honors in health and medicine.

Isotopia Molecular Imaging and Seibersdorf Labor are pleased to announce that they have entered into an agreement for the production of no-carrier-added Lutetium-177, a critical medical radioisotope used in the manufacturing of radiopharmaceuticals for treatment of many types of cancer, including neuroendocrine tumors and prostate cancer.

Today Orexo announced the publication of a manuscript, " A Personalized, Interactive, Cognitive-Behavioral Therapy-Based Digital Therapeutic

Pharnext SA today announces the publication of the data from the Company’s first phase III placebo-controlled clinical study of PXT3003 in Charcot-Marie-Tooth disease Type 1A (‘CMT1A’)

Vomaris Innovations, Inc. announces the first patient enrollment in a study using its bioelectric antimicrobial wound care technology following surgical treatment for Hidradenitis Suppurativa (HS).